Company: GANX
Filing Date: 2025-08-12
Form Type: 10-Q
Source: 0001558370-25-011220
Chunk: 6

Company: Gain Therapeutics, Inc.
Filing Date: 2025-08-12
Form: 10-Q
Item: Part II, Item 1L
Chunk 6
---
Item 1. Legal Proceedings.

As previously disclosed, the Company and two members of its board of directors were named as defendants in a lawsuit filed in the Circuit Court of Maryland for Montgomery County by Matthias Alder, the Company’s former Chief Executive Officer. Following mediation, the parties reached an agreement in principle to settle the case and subsequently executed a settlement agreement resolving and releasing all claims as to all parties. The lawsuit was dismissed with prejudice on July 2, 2025.

Item 1A. Risk Factors.

Our operations and financial results are subject to various risks and uncertainties, including those described in Part I, Item 1A, “Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2024, filed with the SEC on March 27, 2025 and in our Quarterly Report on Form 10-Q for the quarter ended March 31, 2025, filed with the SEC on May 14, 2025. Other than as set forth below, no material changes to such risk factors have occurred during the quarter ended June 30, 2025:

Changes in tax laws could adversely affect our business and financial condition.

Tax legislation continues to evolve globally with new laws and regulations that create uncertainty in the global economy. For example, on July 4, 2025, legislation commonly referred to as the One Big Beautiful Bill Act (the “2025 U.S. Tax Act”) was signed into law, which includes significant provisions, including tax cut extensions and modifications to the international tax framework. While we do not anticipate the 2025 U.S. Tax Act to have a material impact to our financial condition, results of operations, cash flows or effective tax rate, we continue to evaluate the impact of the legislative changes as additional guidance becomes available. Uncertainty remains regarding timing and interpretation by the tax authorities in the affected jurisdictions. Future tax reform and legislative changes could have an adverse impact on our future effective tax rate, tax liabilities, and cash tax. 

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds.

None.